ATOX1

Across TCGA pan-cancer cohorts, ATOX1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATOX1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ATOX1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ATOX1 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

PDAC, LUAD, and HNSC are the cancer types where ATOX1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATOX1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+0.441	<.001	6	view →
LUAD	Male	All	+0.152	<.001	6	view →
HNSC	Male	All	−0.091	.013	4	view →
COAD	All	III,IV	−0.195	.006	3	view →
CCRCC	All	All	−0.107	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATOX1–PDAC

Open the PDAC breakdown →